Rabies causes about 59,000 deaths worldwide each year, and children younger than 15 account for 40% of those deaths. The disease is preventable after exposure when care is started appropriately, but it is fatal in 100% of cases once clinical symptoms appear after infection of the central nervous system. These figures make rabies statistics especially relevant to travelers who may encounter unfamiliar animals or have limited access to urgent medical care.
Rabies statistics at a glance
- 59,000 deaths: WHO’s annual worldwide estimate, reported in 2024 (WHO, “Rabies”).
- 40%: The share of annual rabies deaths attributed to children younger than 15, according to WHO (WHO, “Rabies”).
- More than 150 countries and territories: The geographic reach of rabies as a serious public-health problem in WHO’s 2024 fact sheet (WHO, “Rabies”).
- 99%: The share of human rabies cases caused by dog bites and scratches, according to WHO (WHO, “Rabies”).
- More than 3.7 million disability-adjusted life years: The annual burden cited in the 2018 WHO position paper (WHO, “Rabies vaccines and immunoglobulins”).
- 2030: The target year for the global Zero by 30 goal to eliminate human deaths from dog-mediated rabies (WOAH, “Rabies”).
Global burden and geographic reach
Rabies remains a worldwide health concern, but the reported figures combine different kinds of measurement. The WHO estimate of about 59,000 deaths is an annual global estimate reported in 2024, while the more than 3.7 million disability-adjusted life years figure is an annual estimate cited in a 2018 position paper. They describe burden in different ways and should not be treated as two counts of the same outcome.
The disease affects more than 150 countries and territories. Dogs and dog-related exposures dominate the global picture: WHO attributes 99% of human rabies cases to dog bites and scratches. Once clinical symptoms appear after the virus has infected the central nervous system, rabies is fatal in 100% of cases according to WHO’s current fact sheet. That severe outcome is why prevention and timely post-exposure care are central to travel health planning.
Control programs focus heavily on dogs. WOAH identifies vaccination of at least 70% of dogs in at-risk areas as a level that can reduce human cases to zero. This program threshold is distinct from a worldwide vaccination result; it is a control benchmark for at-risk areas. The Zero by 30 target aims to eliminate human deaths from dog-mediated rabies by 2030.
WHO recognizes two rabies-vaccine administration routes: intradermal and intramuscular. In the 2018 WHO position, an intradermal dose is 0.1 mL, while an intramuscular dose is one complete vial regardless of vial size. Dose volume therefore depends on both the route and the applicable clinical schedule.
Transmission, severity, and exposure patterns
Rabies is associated with animal contact, but the relevant exposure is not limited to a bite. Dog bites and scratches account for the overwhelming majority of human cases globally, while bats are especially important in U.S. surveillance. Among 42 U.S.-acquired human rabies cases reported from 2000 through 2024, bat contact caused 35 cases, or 83% (CDC, “Human Rabies Deaths”). CDC also identified two U.S. human rabies deaths associated with bat contact in 2024.
Public-health officials assessed 384 people after possible contact with bats or infectious patients in the 2024 Minnesota and California events. Of those people, 45, or 12%, were recommended to receive rabies post-exposure prophylaxis (PEP). These event figures describe assessments and recommendations in two specific U.S. events, not the incidence of rabies exposure among all travelers.
The United States recorded 17 human rabies cases from 2015 through 2024, including two contracted outside the country (CDC, “Rabies in the United States: Protecting Public Health”). Rabid bats have been found in all 50 U.S. states except Hawaii. CDC’s current summary also reports that, in the eastern U.S. raccoon-reservoir area, 10% of raccoons that expose people or pets have rabies, while more than 20% of skunks that expose people or pets have rabies.
An exposed dog, cat, or ferret that remains healthy for 10 days is considered not infectious at the time of the exposure under current CDC travel guidance. Without intensive care, the WHO clinical case definition reproduced in the 2026 guidance says death usually occurs within 7–10 days after the first symptoms. These timeframes are clinical and observation definitions, not a guarantee that every exposure will progress on the same schedule.
What the numbers mean for international travelers
CDC identifies three primary traveler animal-contact groups for rabies risk: bats, dogs, and cats. A study cited in the current CDC Yellow Book estimated rabies-exposure incidence among travelers at 0.4% per month of stay. CDC also reports that other studies found most traveler rabies exposures occur within the first two weeks of travel (CDC, “Zoonotic Exposures”). The 0.4% figure is a study estimate, not a universal risk for every destination, itinerary, or traveler.
CDC places selected travelers in PrEP risk category 3 when an elevated rabies-exposure risk persists for more than three years. Risk classification depends on the expected exposure pattern and duration, so a short trip and repeated long-term travel can lead to different prevention discussions.
The post-exposure numbers also differ according to vaccination history. For unvaccinated travelers, CDC lists human rabies immune globulin (RIG) at 20 IU/kg and equine RIG at 40 IU/kg. After exposure, CDC recommends one RIG dose on day 0, infiltrated into the wound when possible, for an unvaccinated traveler. For previously vaccinated travelers, CDC recommends two vaccine doses and zero RIG doses after exposure.
The evidence summaries include safety-related statistics. Approximately 6% of people receiving HDCV booster vaccinations experience systemic hypersensitivity reactions. Reported adverse-event incidence after modern equine-derived rabies immunoglobulin is 0.8%–6.0%. These are reported evidence ranges and should not be interpreted as a personal risk prediction.
Post-exposure prophylaxis schedules
Immediate wound care is part of the response. WHO recommends washing and flushing rabies-exposure wounds for approximately 15 minutes. The vaccine and immunoglobulin schedules below come from different authorities and routes, so they should not be combined into a single universal regimen.
| Situation or schedule | Timing | Quantity described by the source |
|---|---|---|
| WHO intradermal PEP, unvaccinated | Days 0, 3, and 7 | Two injection sites per visit, 0.1 mL at each site |
| WHO intradermal PEP, previously immunized | Days 0 and 3 | One injection site per visit, 0.1 mL at the site |
| CDC U.S. PEP, immunocompetent and unvaccinated | Days 0, 3, 7, and 14 | Four 1.0-mL vaccine doses, plus one RIG dose on day 0 |
| CDC U.S. PEP, immunocompromised and unvaccinated | Days 0, 3, 7, 14, and 28 | Five vaccine doses |
| CDC U.S. PEP, previously vaccinated | Days 0 and 3 | Two 1.0-mL vaccine doses and zero RIG doses |
The WHO one-week intradermal PEP schedule uses two injection sites on days 0, 3, and 7. Each site receives 0.1 mL. For someone already immunized, WHO reduces the intradermal schedule to one site on days 0 and 3, also using 0.1 mL at the single site.
CDC’s standard U.S. course for an immunocompetent, unvaccinated person contains four 1.0-mL doses on days 0, 3, 7, and 14. CDC adds a fifth vaccine dose on day 28 for immunocompromised patients. For a previously vaccinated traveler, the U.S. schedule is two 1.0-mL doses on days 0 and 3. CDC recognizes three ways to qualify as previously vaccinated: prior PrEP, prior PEP, or another rabies vaccine plus a documented positive antibody response.
Pre-exposure vaccination and antibody thresholds
The 2022 U.S. ACIP schedule changed rabies PrEP from three doses to two. The current U.S. primary series gives the doses on days 0 and 7. CDC says data strongly support three years of immunity for this two-dose series. HDCV and PCEC PrEP products listed by CDC each use a 1.0-mL dose (CDC, “Rabies”).
For travelers with sustained risk, CDC calls for either a titer at 1–3 years or a third dose between day 21 and year 3. After a recognized exposure, a person considered pre-exposure vaccinated still receives two vaccine doses on days 0 and 3. Pre-exposure vaccination reduces the post-exposure regimen in the CDC guidance; it does not remove the need for medical assessment after a recognized exposure.
| U.S. PrEP risk category | Antibody monitoring or booster guidance |
|---|---|
| Category 1 | Check titers every 6 months; give a booster below 0.5 IU/mL |
| Category 2 | Check titers every 2 years; give a booster below 0.5 IU/mL |
| Category 3 | One titer check during years 1–3 after the primary two-dose series |
| Category 4 | Exposure expected for no more than 3 years after the primary series; no routine booster |
These categories describe U.S. risk guidance from 2022. Category 3 applies to travelers whose elevated exposure risk persists for more than three years, while category 4 covers exposure expected to last no more than three years after the primary two-dose series. The 0.5 IU/mL value is the stated booster threshold for categories 1 and 2.
Animal reservoirs, surveillance, and control
Wild animals account for more than 90% of reported U.S. rabies cases. CDC’s U.S. exposure breakdown attributes 35% to bats, 29% to raccoons, 17% to skunks, and 8% to foxes. These percentages describe the U.S. breakdown in the CDC summary and should not be generalized to the global dog-mediated rabies burden.
U.S. prevention and surveillance operate at substantial scale. The wildlife rabies program distributes more than 7 million vaccine baits each year. More than 130 U.S. laboratories test nearly 100,000 animals for rabies annually, and more than 3,500 animals test positive in a typical U.S. year. CDC’s National Rabies Surveillance System works with 54 U.S. public-health jurisdictions.
Together, these figures show why traveler advice emphasizes avoiding contact with bats, dogs, and cats, arranging prompt wound care after a possible exposure, and knowing whether prior vaccination changes the PEP schedule. The global burden, the U.S. wildlife pattern, and the vaccination guidance measure different populations and periods, but each points to the same practical issue: exposure decisions need to be made quickly and with the applicable local protocol.